Handelsavisen
prelaunch
Companies ›Healthcare ›246960.KQ
24
246960.KQ — KOSDAQ Pharmaceuticals

SCL Science Inc

$1 731,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-47,9 %
ROE
-3,4 %
Net margin
-54,5 %
Debt / equity
0,44
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

SCL Science Inc is a pharmaceutical company that develops and commercializes therapeutic products, primarily in the healthcare sector.

Business. SCL Science Inc is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ under the ticker symbol 246960.KQ. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-3,4 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 246960.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 246960.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    SCL Science Inc is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ under the ticker symbol 246960.KQ. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    SCL Science Inc has a liquidity position that is below the industry median, with a current ratio of 2.44 and a negative net cash position after subtracting total debt. The company's cash and equivalents amount to KRW 768.1 million, while its long-term debt stands at KRW 7,984.5 million. The liquidity risk is moderate, as the company has a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure.

    The company's profitability is weak, with a return on equity of -3.38% and a return on assets of -2.07%. These figures are significantly below the industry median for pharmaceutical companies, which typically report positive returns. The operating loss of KRW 542.7 million and a net loss of KRW 618.0 million further highlight the company's financial challenges.

    SCL Science Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification provided in the available data, suggesting that the company's operations are primarily localized. This lack of diversification could expose the company to regional economic or regulatory risks.

    The company's growth trajectory is negative, with a net loss in the most recent reporting period. The operating cash flow is negative at KRW -1,415.98 million, and the free cash flow is also negative at KRW -797.4 million. These figures indicate that the company is not generating sufficient cash from operations to sustain its activities or fund growth.

    The risk assessment for SCL Science Inc indicates a medium liquidity risk and a low dilution risk. The company's key financial flag is the negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution risk is low, as there is no indication of significant share issuance or dilution potential in the near term.

    Recent events related to SCL Science Inc include the filing of its latest financial statements, which show a continued operating loss and negative cash flows. There are no recent transcripts or press releases indicating significant strategic changes or new product launches. The company's financial performance remains a concern, and investors should monitor its ability to improve profitability and cash flow generation.

    Key takeaways
    • SCL Science Inc is a pharmaceutical company with a weak profitability profile, as evidenced by a negative return on equity and return on assets.
    • The company's liquidity position is moderate, with a current ratio of 2.44, but it has a negative net cash position after subtracting total debt.
    • SCL Science Inc's revenue is concentrated in a single business segment, and there is no geographic diversification disclosed.
    • The company's growth trajectory is negative, with a net loss and negative operating and free cash flows in the most recent reporting period.
    • The risk assessment indicates a medium liquidity risk and a low dilution risk, with the key financial flag being the negative net cash position after subtracting total debt.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Revenue surged 364.6% year-over-year to 22 billion KRW, demonstrating significant top-line growth momentum.

    Free cash flow improved by 32.0% year-over-year, indicating better cash generation despite ongoing losses.

    Operating income improved by 6.2% year-over-year, suggesting a slight stabilization in core operational performance.

    Cash conversion ratio of 2.29 ranks in the top quartile among pharmaceutical peers.

    Debt-to-equity ratio of 0.44 remains below the pharmaceutical cohort median of 0.18.

    BEAR CASE · 2

    The company faces high credit risk, signaling potential difficulties in meeting financial obligations.

    Long-term debt increased significantly to 32.4 billion KRW, reflecting rising leverage pressures.

    In focus — financials by report

    Valuation FY

    Market price
    $1 731,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $18.31B
    Net cashⓘ
    -$7.22B
    Current ratioⓘ
    2.4
    Debt / equityⓘ
    0.4
    ROAⓘ
    -2.1%
    ROEⓘ
    -3.4%
    Cash conversionⓘ
    229.0%
    CapEx / revenueⓘ
    -37.7%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-47,9 %Bottom quartile
    Net Margin-54,5 %Bottom quartile
    ROE-3,4 %Below median
    Capex / Rev-37,7 %Bottom quartile
    D/E0,44Below median
    Cash Conv2,29Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • SCL Science Inc Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    246960.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage